ement of Operations, and are not included above the operating income (loss) line for year over year comparative purposes. As noted at the time of the announced sale of Stellacure, the realigned Company is stronger moving forward. Shedding the liabilities of Stellacure was also a key driver in improving the balance sheet of the Company by reversing a stockholder's deficit position at the end of 2011 of $.88 million to a stockholder equity position of $1.3 million; an improvement of $2.1 million in the nine month period.
Mr. Vicente concluded, "We will continue to focus on the fundamentals of performance. We are confident this is the path to increasing shareholder value, while we also understand the urgency associated with this mission. We are confident in our strategy and we need to continue to deliver improved results."
About Cord Blood America
Cord Blood America, Inc. is the parent company of CorCell, Companies, Inc. which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. and CorCell Companies, Inc., visit our websites: http://www.cordblood-america.com/ for investor information and http://www.corcell.com/ for customer information.
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the
Page: 1 2 3 Related biology technology :1
|SOURCE Cord Blood America, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. FindTheBest Helps Parents Find Cord Blood Banks2
. Cord Blood America Announces DTCC Removes "Chill" Imposed in December 20103
. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results4
. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 20115
. Study finds chronic abnormal brain blood flow in Gulf War veterans6
. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting7
. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells8
. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development9
. NxStage Extends Agreement to Supply Streamline Bloodlines, MasterGuard and Buttonhole Needle Technology to B. Braun10
. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients11
. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION